12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AFN-1252: Phase IIa data

An open-label, U.S. and Canadian Phase IIa trial in 103 patients with ABSSSI due to Staphylococcus showed that twice-daily 200 mg oral AFN-1252 for 5-14 days led to an overall cure rate, defined as resolution of lesions within 5-10 days after the...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >